Alyssa M. Peckham

1.4k total citations
38 papers, 1.0k citations indexed

About

Alyssa M. Peckham is a scholar working on Public Health, Environmental and Occupational Health, Emergency Medicine and Anesthesiology and Pain Medicine. According to data from OpenAlex, Alyssa M. Peckham has authored 38 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Public Health, Environmental and Occupational Health, 14 papers in Emergency Medicine and 13 papers in Anesthesiology and Pain Medicine. Recurrent topics in Alyssa M. Peckham's work include Opioid Use Disorder Treatment (28 papers), Poisoning and overdose treatments (12 papers) and Pain Management and Opioid Use (8 papers). Alyssa M. Peckham is often cited by papers focused on Opioid Use Disorder Treatment (28 papers), Poisoning and overdose treatments (12 papers) and Pain Management and Opioid Use (8 papers). Alyssa M. Peckham collaborates with scholars based in United States, United Kingdom and Germany. Alyssa M. Peckham's co-authors include Kirk E. Evoy, David A. Sclar, Jordan R. Covvey, Kathleen A. Fairman, Leslie Ochs, Douglas L. Boggs, Kelly R. Reveles, Kellie J. Goodlet, Sarah E. Wakeman and Kevin Tidgewell and has published in prestigious journals such as Drugs, Drug and Alcohol Dependence and Drug Safety.

In The Last Decade

Alyssa M. Peckham

38 papers receiving 977 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alyssa M. Peckham United States 19 528 259 196 151 149 38 1.0k
Kirk E. Evoy United States 18 581 1.1× 250 1.0× 192 1.0× 127 0.8× 211 1.4× 48 1.2k
Emily A. Karanges Australia 15 339 0.6× 171 0.7× 210 1.1× 247 1.6× 92 0.6× 30 1.3k
Jeffrey Gudin United States 18 535 1.0× 396 1.5× 181 0.9× 46 0.3× 162 1.1× 62 1.2k
Rabia S. Atayee United States 18 397 0.8× 275 1.1× 254 1.3× 85 0.6× 35 0.2× 76 1.1k
Shanthi Mogali United States 12 547 1.0× 184 0.7× 145 0.7× 72 0.5× 308 2.1× 18 1.0k
Émilie Jouanjus France 19 389 0.7× 108 0.4× 174 0.9× 141 0.9× 188 1.3× 58 1.1k
Bridin Murnion Australia 19 419 0.8× 256 1.0× 205 1.0× 164 1.1× 256 1.7× 65 1.7k
Mindy L. McEntee United States 11 630 1.2× 357 1.4× 153 0.8× 64 0.4× 185 1.2× 24 1.3k
Carl L. Roland United States 17 846 1.6× 642 2.5× 333 1.7× 90 0.6× 364 2.4× 55 1.6k
Gail K. Strickler United States 13 485 0.9× 167 0.6× 138 0.7× 48 0.3× 294 2.0× 21 824

Countries citing papers authored by Alyssa M. Peckham

Since Specialization
Citations

This map shows the geographic impact of Alyssa M. Peckham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alyssa M. Peckham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alyssa M. Peckham more than expected).

Fields of papers citing papers by Alyssa M. Peckham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alyssa M. Peckham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alyssa M. Peckham. The network helps show where Alyssa M. Peckham may publish in the future.

Co-authorship network of co-authors of Alyssa M. Peckham

This figure shows the co-authorship network connecting the top 25 collaborators of Alyssa M. Peckham. A scholar is included among the top collaborators of Alyssa M. Peckham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alyssa M. Peckham. Alyssa M. Peckham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Covvey, Jordan R., et al.. (2022). Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. Research in Social and Administrative Pharmacy. 19(4). 599–609. 4 indexed citations
3.
Evoy, Kirk E., et al.. (2021). Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Mental Health Clinician. 11(4). 225–230. 6 indexed citations
4.
Peckham, Alyssa M., et al.. (2021). Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: A retrospective case series. Journal of Substance Abuse Treatment. 126. 108316–108316. 26 indexed citations
5.
Weimer, Melissa B., et al.. (2021). Low Dose Initiation of Buprenorphine: A Narrative Review and Practical Approach. Journal of Addiction Medicine. 16(4). 399–406. 39 indexed citations
6.
Noor‐E‐Alam, Md., et al.. (2021). Patterns of patient discontinuation from buprenorphine/naloxone treatment for opioid use disorder: A study of a commercially insured population in Massachusetts. Journal of Substance Abuse Treatment. 131. 108416–108416. 8 indexed citations
7.
Barner, Jamie C., et al.. (2021). Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. Clinical Drug Investigation. 41(3). 245–253. 10 indexed citations
8.
Evoy, Kirk E., Jordan R. Covvey, Alyssa M. Peckham, & Kelly R. Reveles. (2021). Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. International Journal of Clinical Pharmacy. 43(4). 1055–1064. 22 indexed citations
9.
Evoy, Kirk E., Laura Roccograndi, Charles E. Leonard, et al.. (2020). National outpatient medication utilization for opioid and alcohol use disorders from 2014 to 2016. Journal of Substance Abuse Treatment. 119. 108141–108141. 4 indexed citations
10.
Peckham, Alyssa M., et al.. (2020). Opportunities to Offer Harm Reduction to People who Inject Drugs During Infectious Disease Encounters: Narrative Review. Open Forum Infectious Diseases. 7(11). ofaa503–ofaa503. 21 indexed citations
11.
Peckham, Alyssa M., et al.. (2019). High-risk opioid prescribing trends in the outpatient setting prior to issuance of federal guidance. Preventive Medicine Reports. 15. 100892–100892. 4 indexed citations
12.
Peckham, Alyssa M., et al.. (2019). Evaluation of a peer- and self-grading process for clinical writing assignments. Currents in Pharmacy Teaching and Learning. 11(10). 979–986. 5 indexed citations
13.
Peckham, Alyssa M., Kirk E. Evoy, Leslie Ochs, & Jordan R. Covvey. (2018). Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. Substance Abuse Research and Treatment. 12. 620358815–620358815. 75 indexed citations
14.
Peckham, Alyssa M., et al.. (2018). VMAT2 Inhibitors for Tardive Dyskinesia—Practice Implications. Journal of Pharmacy Practice. 32(4). 450–457. 8 indexed citations
15.
Peckham, Alyssa M., et al.. (2018). Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Management and Healthcare Policy. Volume 11. 109–116. 71 indexed citations
16.
Evoy, Kirk E., et al.. (2018). Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Research in Social and Administrative Pharmacy. 15(8). 953–958. 74 indexed citations
17.
Fairman, Kathleen A., et al.. (2018). Use of power-law analysis to predict abuse or diversion of prescribed medications: proof-of-concept mathematical exploration. BMC Research Notes. 11(1). 523–523. 1 indexed citations
18.
Peckham, Alyssa M., et al.. (2018). Kappa opioid receptor antagonism: Are opioids the answer for treatment resistant depression?. Mental Health Clinician. 8(4). 175–183. 20 indexed citations
19.
Peckham, Alyssa M., Kathleen A. Fairman, & David A. Sclar. (2017). Prevalence of Gabapentin Abuse: Comparison with Agents with Known Abuse Potential in a Commercially Insured US Population. Clinical Drug Investigation. 37(8). 763–773. 39 indexed citations
20.
Peckham, Alyssa M., Kathleen A. Fairman, & David A. Sclar. (2017). All-Cause and Drug-Related Medical Events Associated with Overuse of Gabapentin and/or Opioid Medications: A Retrospective Cohort Analysis of a Commercially Insured US Population. Drug Safety. 41(2). 213–228. 69 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kirk E. Evoy Breakdown of academic impact, for papers by Emily A. Karanges Breakdown of academic impact, for papers by Jeffrey Gudin Breakdown of academic impact, for papers by Rabia S. Atayee Breakdown of academic impact, for papers by Shanthi Mogali Breakdown of academic impact, for papers by Émilie Jouanjus Breakdown of academic impact, for papers by Bridin Murnion Breakdown of academic impact, for papers by Mindy L. McEntee Breakdown of academic impact, for papers by Carl L. Roland Breakdown of academic impact, for papers by Gail K. Strickler
Rankless by CCL
2026